A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. (12th June 2019)